Merrill reiterates UCB at buy

UCB was reiterated by Merrill Lynch analyst Erica Whittaker at a buy rating with a €48 price target after an article in a medical journal demonstrated superior retention rates for Keppra over three years compared to other epilepsy drugs. Retention rates can provide a good indication of efficacy and tolerability in day-to-day clinical practice. Keppra's expansion into the epilepsy market could result in sales that surprise on the upside, Merrill said. Shares of the Brussels, Belgium, biopharmaceutical company were up €0.69, or 1.7%, at €41.36.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.